CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)
Go back to CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)| CARLISLE COMPANIES, Inc. (NYSE: CSL) | Delayed: 334.85 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $334.85 | 52 Week High | $114.49 | |||
| Open | $334.85 | 52 Week Low | $75.17 | |||
| Day High | $334.85 | P/E | 92.76 | |||
| Day Low | $334.85 | EPS | $3.61 | |||
| Volume | 481 | |||||
| (AMEX: CSLLY) | Delayed: 30.63 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $30.63 | 52 Week High | $45.60 | |||
| Open | $30.63 | 52 Week Low | $33.39 | |||
| Day High | $30.63 | P/E | N/A | |||
| Day Low | $30.63 | EPS | $0.00 | |||
| Volume | 5,706 | |||||
